Vimarsana
Biggest News Aggregation in the World

Keystone Heart News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Keystone Heart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Keystone Heart Today - Breaking & Trending Today

Valcare Medical, Inc. Announces Corporate Restructuring and Appointment of New CEO - Vimarsana News

Valcare Medical, Inc. Announces Corporate Restructuring and Appointment of New CEO

/PRNewswire/ -- Valcare Medical, Inc., a leading innovator in transcatheter-based mitral solutions, today announced a comprehensive corporate restructure by a...

New Guidance on Discussing Brain Atrophy With MS Patients - Vimarsana News

New Guidance on Discussing Brain Atrophy With MS Patients

New recommendations help clinicians communicate technical information to help patients with multiple sclerosis achieve better understanding and self-care.

Prudence or Spin? Mulling Embolic Protection After PROTECTED TAVR - Vimarsana News

Prudence or Spin? Mulling Embolic Protection After PROTECTED TAVR

Experts discuss how the results were conveyed and what they mean for embolic protection during TAVI moving forward.

Source: tctmd.com
DGAP-News: SafeHeal Appoints Medical Device Industry Veteran Chris Richardson as Chief Executive Officer Seite 1 - Vimarsana News

DGAP-News: SafeHeal Appoints Medical Device Industry Veteran Chris Richardson as Chief Executive Officer Seite 1

11.07.2022 - DGAP-News: SafeHeal / Key word(s): Personnel SafeHeal Appoints Medical Device Industry Veteran Chris Richardson as Chief Executive Officer 11.07.2022 / 15:00 The issuer is solely responsible for the content of this announcement. SafeHeal Appoints ... Seite 1

No Stroke Reduction With Embolic Protection in TAVI, Two Studies Suggest - Vimarsana News

No Stroke Reduction With Embolic Protection in TAVI, Two Studies Suggest

The registry data and meta-analysis aren’t definitive, and clearer answers are anticipated from the PROTECTED-TAVR trial.

Source: tctmd.com